Oral (capsule) BPC-157 has animal evidence for gut-local effects because the peptide shows unusual resistance to gastric acid, but human bioavailability data is entirely absent
References: Jastreboff AM, et al
It is therefore not possible to guarantee a particular outcome or duration of benefit
Adding KPV to a BPC-157 protocol makes sense for inflammatory conditions, particularly in the gut
Originally derived from gastric proteins, BPC-157 works systemically to promote blood flow, tissue repair, and cellular regenerationmaking it highly valuable for patients dealing with injuries, chronic inflammation, gastrointestinal dysfunction, or delayed recovery
Intramuscular injections are touted as being easier to administer than intravenous, partly because of the easy access of the thigh muscles